VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications expected to enter Phase 1 this year that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease.
Location: Israel, Center District, Modiin-Maccabim-Reut
Employees: 11-50
Total raised: $16.92M
Founded date: 2000
Investors 1
| Date | Name | Website |
| - | Aurum Vent... | aurum.co.i... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.12.2021 | - | $16.92M | - |
Mentions in press and media 3
| Date | Title | Description |
| 09.03.2023 | VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash | - |
| 16.02.2023 | VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash | - |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |